Home Cart Sign in  
Chemical Structure| 69839-83-4 Chemical Structure| 69839-83-4

Structure of Didox
CAS No.: 69839-83-4

Chemical Structure| 69839-83-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Didox can prevent LPS-induced NF-KB activation and translocation of NF-kappa beta p65 subunits.

Synonyms: NSC-324360

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Didox

CAS No. :69839-83-4
Formula : C7H7NO4
M.W : 169.13
SMILES Code : O=C(NO)C1=CC=C(O)C(O)=C1
Synonyms :
NSC-324360
MDL No. :MFCD01667810
InChI Key :QJMCKEPOKRERLN-UHFFFAOYSA-N
Pubchem ID :3045

Safety of Didox

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Didox

DNA
pyroptosis

Isoform Comparison

Biological Activity

Target
  • ribonucleotide reductase

In Vitro:

Cell Line
Concentration Treated Time Description References
ARPE-19 epithelial cells 182 ± 23 µM (EC50) 14 days To evaluate the anti-HCMV activity of Didox when used alone, the results showed an EC50 of 182 ± 23 µM in ARPE-19 cells. Antiviral Res. 2013 Oct;100(1):151-8.
MRC-5 fibroblasts 82 ± 32 µM (EC50) 14 days To evaluate the anti-HCMV activity of Didox when used alone, the results showed an EC50 of 82 ± 32 µM in MRC-5 cells. Antiviral Res. 2013 Oct;100(1):151-8.
T-cells (B10.D2 and C57BL6 mice) 25 µM - 100 µM 24 - 48 hours Didox significantly inhibited the secretion of cytokines IL-6, IFN-γ, TNF-α, IL-2, IL-13, IL-10 and IL-4. J Inflamm (Lond). 2010 Aug 18;7:43.
Mouse embryonic fibroblast (MEF) 25 µM - 100 µM 24 - 96 hours Didox significantly inhibited T-cell proliferation, with 25μM concentration reducing proliferation by approximately 90% at 96 hours post stimulation, and 50μM concentration completely blocking proliferation. J Inflamm (Lond). 2010 Aug 18;7:43.
MDA-MB-468 30-600 µM 24 hours Didox downregulates cyclin D1, cyclin A2, and cyclin E2, along with NF-κB signaling proteins p100, p105, and RelB, and increases Rb and pRb S807 expression. Cancers (Basel). 2024 Feb 28;16(5):975.
MCF7 30-600 µM 24 hours Didox downregulates an element of the cell cycle checkpoint, cyclin D1, accompanied by a reduction in NF-κB activity and induces cell cycle arrest at G1. Cancers (Basel). 2024 Feb 28;16(5):975.
Mouse primary cardiomyocytes 1 µM 24 hours To investigate the effect of DOX on RRM2 expression, results showed decreased RRM2 mRNA and protein levels Biomolecules. 2022 Feb 12;12(2):299.
RAW264.7 macrophages 50 µM 24 hours To evaluate the effects of Didox on LPS-induced inflammation and oxidative stress. Results showed that Didox significantly inhibited the mRNA expression of iNOS, IL-6, TNF-α, and COX-2, and reduced the secretion of NO, IL-6, and IL-10. Chem Biol Interact. 2015 May 25;233:95-105.
HuH7 cells 1, 10, 25, 50, 100, 200 and 500 µM 24, 48 and 72 hours Didox showed similar sensitivity in HuH7 cells with IC50 of 329.31 ± 31.55 µM at 48 h and 122.92 ± 13.21 µM at 72 h. Pharmaceuticals (Basel). 2019 Sep 2;12(3):129.
HA22T/VGH cells 1, 10, 25, 50, 100, 200 and 500 µM 24, 48 and 72 hours Didox reduced cell viability in a dose- and time-dependent manner with IC50 of 283.36 ± 18.82 µM at 48 h and 132.98 ± 7.97 µM at 72 h. Pharmaceuticals (Basel). 2019 Sep 2;12(3):129.
SH-SY5Y 10 µM 3 hours To evaluate the activation effect of Didox on HIF1 ODD-luc and Neh2-luc reporters. Results showed that Didox activated HIF1 ODD-luc reporter at concentrations above 100 µM but had no effect on Neh2-luc reporter. Aging Dis. 2016 Dec 1;7(6):745-762.
MRC-5 fibroblasts 103 ± 19 µM (EC50) 5 days To evaluate the anti-HCMV activity of Didox when used alone, the results showed an EC50 of 103 ± 19 µM in MRC-5 cells. Antiviral Res. 2013 Oct;100(1):151-8.
Peritoneal mast cells 100 µM 6 hours Didox significantly suppressed IL-33-induced IL-6 production Cell Immunol. 2017 Sep;319:10-16.
Bone marrow derived mast cells (BMMC) 100 µM 6 hours Didox significantly suppressed IL-33-induced production of IL-6, IL-13, TNF, and MIP-1α Cell Immunol. 2017 Sep;319:10-16.
Peritoneal mast cells 100 µM 6 hours Didox suppressed IgE-mediated IL-6 and IL-13 secretion but had no significant effect on MCP-1. Cell Immunol. 2017 Dec;322:41-48.
Mouse bone marrow-derived mast cells (BMMC) 100 µM 6 hours Didox suppressed IgE-stimulated degranulation and cytokine production, including IL-6, IL-13, TNF, and MIP-1a. Cell Immunol. 2017 Dec;322:41-48.
HT-29 501.6 ± 53 µM (IC50) 72 hours To evaluate the cytotoxic effect of Didox on HT-29 cells, results showed an IC50 of 501.6 ± 53 μM for Didox alone. Sci Rep. 2016 Nov 14;6:36855.
HCT 116 105 ± 1.5 µM (IC50) 72 hours To evaluate the cytotoxic effect of Didox on HCT 116 cells, results showed an IC50 of 105 ± 1.5 μM for Didox alone. Sci Rep. 2016 Nov 14;6:36855.
MCF-7 cells 9.506 ± 0.08 μg/ml (IC50) 72 hours Evaluate the effect of Didox on Herceptin cytotoxicity, results showed that Didox combined with Herceptin significantly reduced the IC50 value, indicating synergistic effect Sci Rep. 2015 Jul 9;5:12054.
T47D cells 82.975 ± 5.95 μg/ml (IC50) 72 hours Evaluate the effect of Didox on Herceptin cytotoxicity, results showed that Didox combined with Herceptin significantly reduced the IC50 value, indicating synergistic effect Sci Rep. 2015 Jul 9;5:12054.
H9C2 cells 60 µM To investigate the effect of RRM2 on cell proliferation, results showed RRM2 overexpression reduced adverse effects of DOX on proliferation Biomolecules. 2022 Feb 12;12(2):299.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57/B6 mice DOX-induced cardiomyopathy model Intraperitoneal injection 15 mg/kg 5 days To investigate the role of RRM2 in DOX-induced cardiomyopathy, results showed RRM2 overexpression alleviated myocardial injury Biomolecules. 2022 Feb 12;12(2):299.
Mice (C57BL6 and B10.D2) Mixed lymphocyte reaction (MLR) model In vitro culture 25 μM - 100 μM Single treatment, lasting 6 days Didox significantly inhibited T-cell proliferation and cytokine secretion in MLR, with 100μM dose inhibiting IFN-γ and IL-2 production to levels comparable to normal controls. J Inflamm (Lond). 2010 Aug 18;7:43.
Mice LPS-induced neuroinflammation model Intraperitoneal injection 250 mg/kg Starting 24 h post-LPS injection and continued for 6 days Didox treatment reversed AIS disruption and accelerated AIS recovery. J Neuroinflammation. 2017 Jun 8;14(1):116
C57BL/6J mice IgE-mediated passive systemic anaphylaxis model Intraperitoneal (IP) injection 350 mg/kg Single dose, 6 hours before anaphylaxis induction Didox significantly attenuated the temperature drop in IgE-mediated passive systemic anaphylaxis. Cell Immunol. 2017 Dec;322:41-48.
Nude mice MCF7 PR breast cancer model Intraperitoneal injection 425 mg/kg/day Once daily for 9 days Didox alone or in combination with palbociclib significantly inhibited the growth of ER+ palbociclib-resistant tumors. Cancers (Basel). 2024 Feb 28;16(5):975.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

5.91mL

1.18mL

0.59mL

29.56mL

5.91mL

2.96mL

59.13mL

11.83mL

5.91mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories